

| | REVIEWERS OBSERVATIONS | CORRECTIONS |
|-------------|---|---|
| REVIEWER 1: | Diabetic enteropathy can affect any portion of the gastrointestinal tract. Zavaleta et al summarized that the pathophysiology, symptoms, diagnosis, and treatment of diabetic gastroenteropathy. In section of gastric disorders, authors cited a study of 7107 patients with type 1 diabetes showed that women were more likely to have gastroparesis than men, but less address potential points on sex differentiation. | Correction made in the main document |
| REVIEWER 2 | 1) Abstract should be quantitative as possible for rapid comparison with others studies. The abs should be a mirror of the review and not only a kind of intro, aims or approaches. Incidences and percentages of gastro diabetes should be mention in the abs and also in the intro. | Correction made in the main document |
| | 2) The paper includes an excellent % of references from the last 3 years. However fundamental studies about insulin, diabetes and gastroenteropathy. Furthermore, at the end introduction, it is also not clear what is the main message and relevant points of the review that should be emphasize at this stage. | Correction made in the main document |
| | 3) I would like to make the following suggestion: At the introduction a figure or scheme with the chronology or a timeline about about insulin, diabetes and gastroenteropathy. This year 2021, will be an especially important milestone in Diabetes treatment and research since it will be 100 years since insulin was discovered by Banting, Best and McLeod at the University of Toronto in 1921. Thus, this timeline will also reflect the understanding of the authors about these events and the association with diabetic gastro. This personal view timeline will be interesting and also pedagogical for the others researchers and professors in the field as well as also for others scientists. | A new figure was add in the main document The references were modified |

| | | |
|---------|--|--|
| | 4) Another suggestion is a inclusion of a new figure or a scheme with the structures of all the drugs most used to treat diabetic gastro that were referred within the review. | Drugs are describe in the main document |
| | 5) The figures are good. Some could be globally improved as possible, for instance using letters and sizes not so difficult to see and read, once WJD deserves high quality figures and with rigor would avoid lacking of interest for the figures. | The figures were modified and sent in original version on power point |
| | 6) Globally the conclusion section could follow the discussion, also with perspectives for future research. Eventually, it could be divided in sections with titles highlighting the major observations and take home message within the review. | Correction made in the main document |
| | 7) Please check the year of some references and/or others issues that are absent. | The references were modified |
| EDITOR: | <p>Issues raised:</p> <p>(1) The authors did not provide original pictures. Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor.</p> | <p>The figures were modified and sent in original version on power point</p> <p>Note: All the figures are originals.</p> |

| | | |
|--|--|------------------------------|
| | <p>(2) If an author of a submission is re-using a figure or figures published elsewhere, or that is copyrighted, the author must provide documentation that the previous publisher or copyright holder has given permission for the figure to be re-published; and correctly indicating the reference source and copyrights. For example, “Figure 1 Histopathological examination by hematoxylin-eosin staining (200 ×). A: Control group; B: Model group; C: Pioglitazone hydrochloride group; D: Chinese herbal medicine group. Citation: Yang JM, Sun Y, Wang M, Zhang XL, Zhang SJ, Gao YS, Chen L, Wu MY, Zhou L, Zhou YM, Wang Y, Zheng FJ, Li YH. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(34): 5105-5119. Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc[6]”. And please cite the reference source in the references list. If the author fails to properly cite the published or copyrighted picture(s) or table(s) as described above, he/she will be subject to withdrawal of the article from BPG publications and may even be held liable.</p> | |
| | <p>(3) Authors should always cite references that are relevant to their study. Please check and remove any references that not relevant to this study.</p> | The references were modified |

| Reviewer Comment | Authors action |
|---|-------------------------------|
| Figure 1: timeline. Nothing is referred between 1980 and 2000? Perhaps it could be added any traditional specific drug use in gastro enteropathy and/or diabetes introduced for the first time in practice in that period? perhaps in the XXI century it also could be inserted recent drugs in diabetes such as metformin (2012?)? and/or Glucosidases inhibitors? | It was modified in the figure |
| figures 4 and 5 could be improved. | It was modified in the figure |